[1]. Su Yapeng,Yuan, Dan,Chen, Daniel G, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell, 2022, 185: 881-895.e20. IF=41.582
[2]. Li Dan, Li Nan, Zhang Yi-Fan, et al. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology, 2020, 158: 2250-2265.e20. IF=22.682
[3]. Cordoba Shaun, Onuoha Shimobi, Thomas Simon, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med, 2021, 27: 1797-1805. IF=53.44
[4]. Creelan Benjamin C, Wang Chao, Teer Jamie K, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med, 2021, 27: 1410-1418. IF=53.44
[5]. Diab Adi, Tykodi Scott S, Daniels Gregory A, et al. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. J Clin Oncol, 2021, 39: 2914-2925. IF=44.544
[6]. Su Yapeng, Chen Daniel, Yuan Dan et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell, 2020, 183: 1479-1495.e20. IF=41.582